Here's What Key Metrics Tell Us About Medtronic (MDT) Q3 Earnings

Core Insights - Medtronic reported revenue of $8.29 billion for the quarter ended January 2025, reflecting a year-over-year increase of 2.5$1.39, up from $1.30 in the same quarter last year, resulting in an EPS surprise of +2.21$1.36 [1] Revenue Performance - U.S. Revenue reached $4.24 billion, slightly below the average estimate of$4.28 billion, with a year-over-year change of +2.8% [4] - Worldwide revenue from Diabetes was $694 million, exceeding the average estimate of$676.84 million, marking an increase of +8.4% year over year [4] - Worldwide revenue from Neuroscience was $2.46 billion, matching the six-analyst average estimate, with a year-over-year change of +4.4$3.04 billion, slightly below the estimated $3.05 billion, reflecting a +3.7$2.07 billion, below the average estimate of $2.13 billion, indicating a year-over-year decrease of -3.5$419 million, close to the average estimate of $419.80 million, with a +3$1.55 billion, slightly above the estimated $1.54 billion, showing a +5.1$1.60 billion, below the average estimate of $1.62 billion, reflecting a -1.2% change year over year [4] Stock Performance - Medtronic shares returned +5.4% over the past month, outperforming the Zacks S&P 500 composite's +4.7% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]